Article Text

Download PDFPDF
Allopurinol and the risk of prostate cancer
  1. Shih-Wei Lai1,2,
  2. Yu-Hung Kuo3,
  3. Kuan-Fu Liao4,5
  1. 1 College of Medicine, China Medical University, Taichung, Taiwan
  2. 2 Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
  3. 3 Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan
  4. 4 College of Medicine, Tzu Chi University, Hualien, Taiwan
  5. 5 Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao; kuanfuliaog{at}gmail.com

Statistics from Altmetric.com

Allopurinol is commonly prescribed to treat hyperuricemia. The association between allopurinol use and other comorbidities has been widely explored.1 2 Recently one cohort study revealed that no significant association could be detected between allopurinol use and the risk of prostate cancer (HR=1.03; 95% CI 0.92 to 1.16),3 but another cohort study revealed that long-term use of allopurinol for more than 1 year was associated with a lower risk of prostate cancer in men with gout when compared with …

View Full Text

Footnotes

  • Contributors S-WL contributed to the conception of the article, initiated the draft of the article, and has approved the final draft submitted. Y-HK and K-FL conducted data analysis.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.